What question did this study set out to answer?

This study aims to understand the role of ACE2 in liver fibrosis and its effects on hepatic stellate cells.

May 28, 2009HepatologyOpen Access

Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice #

View Full Paper

Ask AI

Bookmark

Population

Ace2 knockout (KO) mice and wild-type (wt) littermates; murine hepatic stellate cells (HSCs)

Comparison

Gene deletion of ACE2; treatment with… vs Wild-type littermates; untreated controls

Design

Preclinical

Follow-up

up to 1 year, 21 days

Authors

CÖChristoph H. ÖsterreicherMedical University of Vienna KTKojiro TauraKitano Hospital SMSamuele De MinicisOspedale L. Bonomo

Discussion

Member takes

Implication

ACE2 limits experimental hepatic fibrosis in mice; leaves open whether recombinant ACE2 or irbesartan benefits patients with chronic liver disease.

Key Points

This study aims to understand the role of ACE2 in liver fibrosis and its effects on hepatic stellate cells.
Utilized ace2 knockout mice and wild-type littermates to assess liver injury and fibrosis.
Conducted histological analysis and immunoblotting for alpha-SMA and gene expression via qPCR.
Examined the effects of recombinant ACE2 treatment on liver fibrosis in various injury models.
Ace2 knockout mice developed mild hepatic fibrosis, which was prevented by irbesartan treatment.
Increased liver fibrosis in ace2 KO mice after chronic carbon tetrachloride treatment and bile duct ligation (P<0.05).
Administration of recombinant ACE2 reduced experimental fibrosis in cholestatic and toxic liver injury models.

Structured PICO

Population

Ace2 knockout (KO) mice and wild-type (wt) littermates; murine hepatic stellate cells (HSCs)

Intervention

Gene deletion of ACE2; treatment with recombinant ACE2; treatment with irbesartan

Comparator

Wild-type littermates; untreated controls

Outcome

Liver fibrosis and pathology (assessed by histology, immunohistochemistry, alpha-SMA immunoblotting, and qPCR)surrogate

ACE2 acts as a negative regulator of the renin-angiotensin system to limit liver fibrosis, suggesting recombinant ACE2 has therapeutic potential for chronic liver injury.

Cite This Study

Österreicher et al. (2009) studied this question.

synapsesocial.com/papers/6a761934b23c009ac9fbdaa0 https://doi.org/10.1002/hep.23104

View Full Paper

Ask AI

Bookmark

Implication

ACE2 limits experimental hepatic fibrosis in mice; leaves open whether recombinant ACE2 or irbesartan benefits patients with chronic liver disease.

Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice #

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice #

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider